- Home
- ESPR vs MYGN Comparison
ESPR vs MYGN Comparison
Compare ESPR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- MYGN
- Stock Information
- Founded
- ESPR 2008
- MYGN 1991
- Country
- ESPR United States
- MYGN United States
- Employees
- ESPR N/A
- MYGN N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ESPR Health Care
- MYGN Health Care
- Exchange
- ESPR Nasdaq
- MYGN Nasdaq
- Market Cap
- ESPR 660.1M
- MYGN 625.5M
- IPO Year
- ESPR 2013
- MYGN 1995
- Fundamental
- Price
- ESPR $3.68
- MYGN $7.89
- Analyst Decision
- ESPR Buy
- MYGN Hold
- Analyst Count
- ESPR 7
- MYGN 13
- Target Price
- ESPR $6.86
- MYGN $12.58
- AVG Volume (30 Days)
- ESPR 7.0M
- MYGN 1.2M
- Earning Date
- ESPR 11-06-2025
- MYGN 11-03-2025
- Dividend Yield
- ESPR N/A
- MYGN N/A
- EPS Growth
- ESPR N/A
- MYGN N/A
- EPS
- ESPR N/A
- MYGN N/A
- Revenue
- ESPR $303,802,000.00
- MYGN $825,300,000.00
- Revenue This Year
- ESPR $18.83
- MYGN $0.06
- Revenue Next Year
- ESPR N/A
- MYGN $5.68
- P/E Ratio
- ESPR N/A
- MYGN N/A
- Revenue Growth
- ESPR 2.83
- MYGN 0.21
- 52 Week Low
- ESPR $0.69
- MYGN $3.76
- 52 Week High
- ESPR $3.94
- MYGN $16.83
- Technical
- Relative Strength Index (RSI)
- ESPR 71.27
- MYGN 61.94
- Support Level
- ESPR $2.66
- MYGN $6.43
- Resistance Level
- ESPR $3.26
- MYGN $6.89
- Average True Range (ATR)
- ESPR 0.23
- MYGN 0.41
- MACD
- ESPR 0.05
- MYGN 0.15
- Stochastic Oscillator
- ESPR 94.43
- MYGN 91.18
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.